Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Keros Therapeutics, Inc.KROS · Entity 6242 | Director | June 04, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Keros Therapeutics, Inc.
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,958 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Sale · Disposed 2,625 · Balance 10,958 F1: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.61 to $10.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 150,047 |
Reported balance
Holding disclosure · report date 2026-06-04 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 150,047 F3: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 102,233 |
Reported balance
Holding disclosure · report date 2026-06-04 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 102,233 F4: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.61 to $10.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I.
F4: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 8, 2026 20:36 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 2,625 | $10.73 | $28,166.25 |
DisclosureSEC source: 0001808365-26-000004 · form4-06082026_080608.xml · nonDerivative · entry 1 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,958 F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.61 to $10.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:15 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantStock Option (right to buy) · Derivative | 7,433 | $0.00 Strike: $10.50 | $0.00 |
DisclosureSEC source: 0001808365-26-000002 · form4-06052026_040608.xml · derivative · entry 4 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,433 Underlying: Common Stock · 7,433 shares Expires 2036-06-02 F4 · derivative.exercise_date: The option shall vest in equal quarterly installments over the 12 months following June 3, 2026, provided that the grant will in any case be fully vested on the date of Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:15 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantCommon Stock | 7,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001808365-26-000002 · form4-06052026_040608.xml · nonDerivative · entry 1 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,583 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs fully vest on the earlier of (A) June 3, 2027 and (B) the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| November 21, 2025 Filed Dec 18, 2025 21:15 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Disposition to issuerCommon Stock | 130,494 | $17.75 | $2,316,268.50 |
DisclosureSEC source: 0001808365-25-000005 · form4-12182025_041201.xml · nonDerivative · entry 2 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 102,233 F1 · kind: Represents shares tendered and accepted for purchase by the Issuer in a cash tender offer commenced by the Issuer on October 20, 2025. The Issuer announced the final results of the tender offer on November 20, 2025. F3 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| November 21, 2025 Filed Dec 18, 2025 21:15 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Disposition to issuerCommon Stock | 191,527 | $17.75 | $3,399,604.25 |
DisclosureSEC source: 0001808365-25-000005 · form4-12182025_041201.xml · nonDerivative · entry 1 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 150,047 F1 · kind: Represents shares tendered and accepted for purchase by the Issuer in a cash tender offer commenced by the Issuer on October 20, 2025. The Issuer announced the final results of the tender offer on November 20, 2025. F2 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:15 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantStock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $14.82 | $0.00 |
DisclosureSEC source: 0001415889-25-015979 · form4-06062025_040617.xml · derivative · entry 4 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2035-06-03 F4 · derivative.exercise_date: The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:15 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantCommon Stock | 5,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015979 · form4-06062025_040617.xml · nonDerivative · entry 1 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,441 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs fully vest on the earlier of (A) June 4, 2026 and (B) the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:15 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $46.31 | $0.00 |
DisclosureSEC source: 0001415889-24-015153 · form4-06032024_040610.xml · derivative · entry 1 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-05-29 F1 · derivative.exercise_date: The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:42 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $48.79 | $0.00 |
DisclosureSEC source: 0001209191-23-035455 · doc4.xml · derivative · entry 1 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-06-05 F1 · derivative.exercise_date: The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:28 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantStock Options (right to buy) · Derivative | 8,293 | $0.00 Strike: $32.95 | $0.00 |
DisclosureSEC source: 0001209191-22-034048 · doc4.xml · derivative · entry 1 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,293 Underlying: Common Stock · 8,293 shares Expires 2032-05-31 F1 · derivative.exercise_date: The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 00:14 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 435 | $59.00 | $25,665.00 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 24 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 232,727 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.76 to $59.25 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 00:14 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 667 | $59.00 | $39,353.00 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 23 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 341,574 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.76 to $59.25 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 00:14 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 886 | $58.20 | $51,565.20 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 22 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 233,162 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.63 to $58.62 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 00:14 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,356 | $58.20 | $78,919.20 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 21 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 342,241 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.63 to $58.62 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 00:14 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 271 | $57.23 | $15,509.33 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 20 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 234,048 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.63 to $57.56 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 00:14 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 419 | $57.23 | $23,979.37 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 19 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 343,597 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.63 to $57.56 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 00:14 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 2,195 | $58.86 | $129,197.70 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 18 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 234,319 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.57 to $59.36 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 00:14 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 3,367 | $58.86 | $198,181.62 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 17 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 344,016 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.57 to $59.36 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 00:14 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 2,704 | $57.99 | $156,804.96 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 16 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 236,514 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.56 to $58.55 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 00:14 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 4,151 | $57.99 | $240,716.49 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 15 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 347,383 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.56 to $58.55 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 00:14 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,113 | $56.95 | $63,385.35 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 14 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 239,218 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.56 to $57.53 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 00:14 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,707 | $56.95 | $97,213.65 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 13 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 351,534 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.56 to $57.53 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 00:14 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,383 | $56.10 | $77,586.30 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 12 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 240,331 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.555 to $56.53 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 00:14 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 2,124 | $56.10 | $119,156.40 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 11 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 353,241 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.555 to $56.53 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 00:14 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 524 | $54.95 | $28,793.80 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 10 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 241,714 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.50 to $55.48 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 00:14 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 794 | $54.95 | $43,630.30 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 9 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 355,365 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.50 to $55.48 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:14 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 162 | $59.40 | $9,622.80 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 8 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 242,238 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.36 to $59.45 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:14 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 249 | $59.40 | $14,790.60 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 7 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 356,159 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.36 to $59.45 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:14 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 3,412 | $58.96 | $201,171.52 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 6 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 242,400 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.35 to $59.33 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:14 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 5,236 | $58.96 | $308,714.56 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 5 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 356,408 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.35 to $59.33 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:14 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 3,318 | $57.83 | $191,879.94 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 4 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 245,812 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.30 to $58.24 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:14 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 5,094 | $57.83 | $294,586.02 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 3 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 361,644 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.30 to $58.24 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:14 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 2,406 | $56.82 | $136,708.92 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 2 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 249,130 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.30 to $57.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14) and (15). F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:14 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 3,678 | $56.82 | $208,983.96 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 1 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 366,738 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.30 to $57.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14) and (15). F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| December 02, 2021 Filed Dec 3, 2021 22:05 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 90 | $54.67 | $4,920.30 |
DisclosureSEC source: 0001209191-21-067877 · doc4.xml · nonDerivative · entry 16 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 251,536 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.665 to $54.69 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| December 02, 2021 Filed Dec 3, 2021 22:05 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 138 | $54.67 | $7,544.46 |
DisclosureSEC source: 0001209191-21-067877 · doc4.xml · nonDerivative · entry 15 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 370,416 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.665 to $54.69 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| December 02, 2021 Filed Dec 3, 2021 22:05 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 5,705 | $53.86 | $307,271.30 |
DisclosureSEC source: 0001209191-21-067877 · doc4.xml · nonDerivative · entry 14 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 251,626 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.625 to $54.43 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| December 02, 2021 Filed Dec 3, 2021 22:05 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 8,747 | $53.86 | $471,113.42 |
DisclosureSEC source: 0001209191-21-067877 · doc4.xml · nonDerivative · entry 13 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 370,554 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.625 to $54.43 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| December 02, 2021 Filed Dec 3, 2021 22:05 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 4,155 | $53.17 | $220,921.35 |
DisclosureSEC source: 0001209191-21-067877 · doc4.xml · nonDerivative · entry 12 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 257,331 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.61 to $53.605 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| December 02, 2021 Filed Dec 3, 2021 22:05 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 6,372 | $53.17 | $338,799.24 |
DisclosureSEC source: 0001209191-21-067877 · doc4.xml · nonDerivative · entry 11 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 379,301 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.61 to $53.605 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| December 02, 2021 Filed Dec 3, 2021 22:05 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 52 | $52.00 | $2,704.00 |
DisclosureSEC source: 0001209191-21-067877 · doc4.xml · nonDerivative · entry 10 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 261,486 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.58 to $52.57 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| December 02, 2021 Filed Dec 3, 2021 22:05 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 79 | $51.99 | $4,107.21 |
DisclosureSEC source: 0001209191-21-067877 · doc4.xml · nonDerivative · entry 9 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 385,673 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.58 to $52.57 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:05 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,021 | $56.27 | $57,451.67 |
DisclosureSEC source: 0001209191-21-067877 · doc4.xml · nonDerivative · entry 8 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 261,538 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.06 to $57.02 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:05 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,566 | $56.27 | $88,118.82 |
DisclosureSEC source: 0001209191-21-067877 · doc4.xml · nonDerivative · entry 7 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 385,752 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.06 to $57.02 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:05 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,649 | $55.71 | $91,865.79 |
DisclosureSEC source: 0001209191-21-067877 · doc4.xml · nonDerivative · entry 6 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 262,559 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.055 to $56.05 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:05 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 2,528 | $55.71 | $140,834.88 |
DisclosureSEC source: 0001209191-21-067877 · doc4.xml · nonDerivative · entry 5 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 387,318 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.055 to $56.05 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:05 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 3,372 | $54.67 | $184,347.24 |
DisclosureSEC source: 0001209191-21-067877 · doc4.xml · nonDerivative · entry 4 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 264,208 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.055 to $55.05 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:05 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 5,168 | $54.67 | $282,534.56 |
DisclosureSEC source: 0001209191-21-067877 · doc4.xml · nonDerivative · entry 3 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 389,846 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.055 to $55.05 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:05 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 2,766 | $53.48 | $147,925.68 |
DisclosureSEC source: 0001209191-21-067877 · doc4.xml · nonDerivative · entry 2 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 267,580 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.04 to $54.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8), (9), (10) and (11). F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:05 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 4,243 | $53.48 | $226,915.64 |
DisclosureSEC source: 0001209191-21-067877 · doc4.xml · nonDerivative · entry 1 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 395,014 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.04 to $54.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8), (9), (10) and (11). F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.